Please assess the completion status of the following clinical trial:

Trial Title: Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer of the ovaries, fallopian tube or abdominal lining has come back after more than 6 months from the last platinum based chemotherapy treatment.~* Disease must be detected by CT or CA125 level must be elevated or cancerous ascites must be present.~* History of at least one therapy of platinum based chemotherapy.~Exclusion Criteria:~* Participation in another experimental drug study~* Heart disease or high blood pressure~* History of a stroke within the past 6 months~* Vascular disease, or bleeding problems~* Brain cancer~* Major Surgical Procedure within 28 days prior to start date~* Minor surgical procedures within 7 days prior to start date~* Pregnant or lactating~* Abdominal or bowel problems like bleeding~* History of abdominal fistula, GI perforation or Intra-abdominal abscess~* Serious, non-healing wound, ulcer or bone fracture~* Acute hepatitis~* Active infections requiring antibiotics~* Inability to comply with study or follow up procedures

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine/carboplatin/bevacizumab (Type: EXPERIMENTAL): A regimen consisting of gemcitabine(1000 mg/m2)/carboplatin(AUC 3) / bevacizumab(Avastin®)(10mg/kg) will be administered on day 1 and day 15 of a 28 day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).